AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects
Fukase, Hiroyuki, Kajioka, Toshifumi, Oikawa, Ichiro, Ikeda, Naoki, Furuie, HidetoshiJournal:
British Journal of Clinical Pharmacology
DOI:
10.1111/bcp.14151
Date:
October, 2019
File:
PDF, 1.60 MB
2019